Cipla shares slip as Keytruda biosimilar pact with Qilu weighs
Cipla shares traded marginally lower on Friday amid a strong broader market after its partnership with China’s Qilu Pharmaceutical for a Keytruda biosimilar. The new deal is expected to bolster Cipla’s oncology and specialty portfolio in the US.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.